TY - JOUR
T1 - Haematological cancer
T2 - Lenalidomide maintenance-perils of a premature denouement
AU - Rajkumar, S. Vincent
PY - 2012/7
Y1 - 2012/7
N2 - Of three randomized trials testing lenalidomide maintenance in myeloma, a survival benefit is apparent in one. An increased risk of second cancers is seen in all three trials. Maintenance must be considered after a review of risks and benefits, but it is premature to recommend lenalidomide maintenance for all patients.
AB - Of three randomized trials testing lenalidomide maintenance in myeloma, a survival benefit is apparent in one. An increased risk of second cancers is seen in all three trials. Maintenance must be considered after a review of risks and benefits, but it is premature to recommend lenalidomide maintenance for all patients.
UR - http://www.scopus.com/inward/record.url?scp=84863482086&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863482086&partnerID=8YFLogxK
U2 - 10.1038/nrclinonc.2012.100
DO - 10.1038/nrclinonc.2012.100
M3 - Article
C2 - 22665364
AN - SCOPUS:84863482086
SN - 1759-4774
VL - 9
SP - 372
EP - 374
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
IS - 7
ER -